Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Gyre Therapeutics (NASDAQ: GYRE) has successfully closed its public offering of 2,555,555 shares of common stock at $9.00 per share, including the full exercise of underwriters' option for 333,333 additional shares. The offering generated gross proceeds of approximately $23.0 million. Jefferies served as lead book-running manager, with H.C. Wainwright & Co. as co-manager. The proceeds will fund Gyre's Phase 2 clinical trial of F351 for MASH-associated liver fibrosis in the United States, support research and development, manufacturing scale-up, and provide working capital for general corporate purposes. The offering was made pursuant to an effective shelf registration statement filed with the SEC.

Positive

• Successfully raised $23.0 million in gross proceeds through public offering
• Full exercise of underwriters' option indicates strong demand
• Funds secured for Phase 2 clinical trial advancement of F351
• Strengthened balance sheet for R&D and manufacturing scale-up

Negative

• Potential dilution for existing shareholders due to issuance of 2.56 million new shares
• Offering price of $9.00 may represent a discount to market price

News Market Reaction – GYRE

-4.12%

1 alert

-4.12% News Effect

On the day this news was published, GYRE declined 4.12%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that it closed its previously announced underwritten public offering of 2,555,555 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 333,333 shares, at a public offering price of $9.00 per share, less the underwriting discount. The gross proceeds of the offering to Gyre, before deducting underwriting discounts and commissions and other offering expenses payable by Gyre, were approximately $23.0 million.

Jefferies acted as lead book-running manager for the offering and H.C. Wainwright & Co. acted as co-manager for the offering.

Gyre intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and cash flows from operations, to advance its Phase 2 clinical trial of F351 in metabolic dysfunction-associated steatohepatitis (“MASH”)-associated liver fibrosis in the United States, for research and development, manufacturing and scale-up, as well as for working capital and general corporate purposes.

The shares of common stock described above were offered pursuant to a shelf registration statement filed with the Securities and Exchange Commission (“SEC”) that was declared effective by the SEC on November 22, 2024. The offering of the securities was made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement. A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available on the SEC’s website, located at www.sec.gov, and may also be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the U.S. Gyre’s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People’s Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and F230.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning Gyre’s expectations regarding expected use of net proceeds from the offering. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre’s ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre’s capital resources and its ability to raise additional capital. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings Gyre may make with the SEC.

Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:
David Zhang
Gyre Therapeutics
david.zhang@gyretx.com

FAQ

How much money did Gyre Therapeutics (GYRE) raise in its May 2025 public offering?

Gyre Therapeutics raised approximately $23.0 million in gross proceeds through its public offering of 2,555,555 shares at $9.00 per share.

What will Gyre Therapeutics use the proceeds from its 2025 public offering for?

The proceeds will fund Phase 2 clinical trials of F351 in MASH-associated liver fibrosis, support R&D, manufacturing scale-up, and provide working capital for general corporate purposes.

Who were the underwriters for Gyre Therapeutics' May 2025 public offering?

Jefferies acted as lead book-running manager, and H.C. Wainwright & Co. served as co-manager for the offering.

How many additional shares were purchased through the underwriters' option in GYRE's offering?

The underwriters exercised their full option to purchase an additional 333,333 shares.

What is the focus of Gyre Therapeutics' F351 clinical trial?

F351 is being developed for metabolic dysfunction-associated steatohepatitis (MASH)-associated liver fibrosis, with Phase 2 trials planned in the United States.